

ESMO ADVANCED COURSE PROGRAMME

CHOLANGIOCARCINOMA: WHERE ARE WE GOING?

Madrid, Spain
25-26 October 2024

CO-CHAIRS Julien Edeline, France
Angela Lamarca, Spain

SPEAKERS Chiara Braconi, UK
John Bridgewater, United Kingdom
Marine Camus, France
Pilar Del Valle, Spain
Bas Groot Koerkamp, Netherlands
Maeve Lowery, Ireland
Teresa Macarulla, Spain
Victor Moreno, Spain
Lorenza Rimassa, Italy

LEARNING OBJECTIVES

- To understand diagnostic challenges and clinical and molecular differences in cholangiocarcinoma
- To review adjuvant and palliative treatment strategies in patients with cholangiocarcinoma
- To discuss the role of surgery and other locoregional therapy for cholangiocarcinoma
- To investigate the role of immunotherapy for the management of cholangiocarcinoma
- To explore currently available and novel targeted therapies and treatment options for advanced disease

Friday, 25 October 2024

09:00-09:10 **Welcome and introduction**

10' Welcome and learning objectives
Julien Edeline, FR and Angela Lamarca, ES

09:10-10:10 **Session 1 – Understanding biliary tract tumours**

15' What are biliary tract tumors (primary site, epidemiology, and symptoms management)?
Teresa Macarulla, ES

15' The role of endoscopy
Marine Camus, FR

15' The role of specialised nurses
Pilar Del Valle, ES

15' Discussion

10:10-10:40 **Coffee break**

10:40-11:45 **Session 2 – Locoregional and surgical therapies**

20' Locoregional therapy: Is it ready for the clinic?
Julien Edeline, FR

25' Biliary drainage, surgery and transplant
Bas Groot Koerkamp, NL

20' Discussion

11:45-12:45 **Session 3 – Adjuvant and neoadjuvant treatment**

20' Adjuvant treatment: Is capecitabine the standard of care?
John Bridgewater, UK

20' Neoadjuvant treatment: Is perioperative treatment coming or could it have a role?
Lorenza Rimassa, IT

20' Discussion

12:45-13:45 **Lunch**

13:45-14:45 **Session 4 – The management of advanced disease: Chemotherapy and immunotherapy**

20' Chemotherapy - First line and second line: How is the field moving forward?
Angela Lamarca, ES

20' Immunotherapy: Rationale, current data, and upcoming studies
Julien Edeline, FR

20' Discussion

14:45-16:50 **Session 5 – The management of advanced disease: Targeted therapies and new treatment options**

20' Targeted therapies FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development
Maeve Lowery, IE

20' Targeted therapies beyond FGFR and IDH: Current data and compounds in advanced (phase II and beyond) stage of development
Chiara Braconi, UK

20' Discussion

15:45-16:15 **Coffee break**

10' What is coming – Phase I input – Novel IO strategies, cell therapy new compounds in phase I with potential activity
Victor Moreno, ES

10' Ongoing clinical trials – Ongoing and soon-to-come phase II and phase III: To which trials shall I recruit my patients?
Teresa Macarulla, ES

15' Discussion

20:00 **Networking dinner**

Saturday, 26 October 2024

09:00-12:30

Workshop sessions

Three parallel workshop sessions with 20 delegates in each group (delegates will attend all 3 sessions on a rotational basis)

15'	Introduction based on clinical cases presented by speakers
40'	Discussion
5'	Break

Workshop 1

Locoregional disease
John Bridgewater, UK and Lorenza Rimassa, IT

Workshop 2

Palliative chemotherapy (+/- immunotherapy)
Julien Edeline, FR and Angela Lamarca, ES

Workshop 3

Targeted therapy
Chiara Braconi, UK and Maeve Lowery, IE

11:00-11:30

Coffee break

11:30-12:30

Workshops continuation

12:30-13:00

Feedback on the workshops from each group

13:00-13:15

Synthesis and wrap-up

Julien Edeline, FR and Angela Lamarca, ES

13:15-14:15

Lunch